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Abstract Significant hyperglycemia is commonly observed
immediately after solid organ and bone marrow transplant as
well as with subsequent hospitalizations. Surgery and proce-
dures are well known to cause pain and stress leading to se-
cretion of cytokines and other hormones known to aggravate
insulin action. Immunosuppression required for transplant and
preexisting risk are also major factors. Glucose control im-
proves outcomes for all hospitalized patients, including trans-
plant patients, but is often more challenging to achieve be-
cause of frequent and sometimes unpredictable changes in
immunosuppression doses, renal function, and nutrition. As
a result, risk of hypoglycemia can be greater in this patient
group when trying to achieve glucose control goals for hospi-
talized patients. Key to successful management of hypergly-
cemia is regular communication between the members of the
care team as well as anticipating and rapidly implementing a
new treatment paradigm in response to changes in immuno-
suppression, nutrition, renal function, or evidence of changing
insulin resistance.
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Introduction
Surgeries of all kinds and post-operative pain have been
long shown to increase risk of hyperglycemia by triggering
cytokines and stress hormones known to aggravate insulin
action [1]. Thus, it is not surprising that hyperglycemia
occurs after major operations required for solid organ trans-
plant. But, as the numbers of solid organ transplants and
bone marrow transplants performed each year continue to
grow, and transplant recipients live longer, more transplant
patients will require management of glucose not only after
their initial transplant procedure but also after subsequent
hospitalizations for episodes of care that may or may not be
related to their transplant. Current immunosuppression reg-
imens contribute to hyperglycemia in organ transplant pa-
tients, as does preexisting risk.
Diabetes is common among transplant candidates, but
some recipients are first recognized as having diabetes only
after transplant. Diabetes that is first diagnosed after trans-
plant, previously called New Onset Diabetes After Transplan-
tation (NODAT), may be new onset but could also represent
previously unrecognized diabetes, so a recent international
consensus panel suggested changing the name to post-
transplant diabetes mellitus (PTDM) [2, 3•]. Hyperglycemia
is also common immediately after solid organ and bone mar-
row transplant, with a frequency reported at 80–90 % or more
for kidney transplant recipients in the first days to week fol-
lowing transplant [4, 5•] but may resolve after immunosup-
pression doses are reduced. Thus, the diagnosis of PTDM
should be reserved for hyperglycemia that persists after the
recipient has been reduced to maintenance immunosuppres-
sion doses. The incidence of PTDM using these new guide-
lines is as yet unknown, but the increasing frequency of obe-
sity, the significant impact of current immunosuppression reg-
imens on insulin secretion and action, and the greater scrutiny
of glucose control in all hospitalizations have led to the
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recognition that significant hyperglycemia is very common in
the immediate post-transplant hospitalization.
With this background, whether treating preexisting diabe-
tes, post-transplant diabetes, or new hyperglycemia that may
be diagnosed as post-transplant diabetes at a later time, man-
agement of hyperglycemia in the transplant patient is common
and important. This chapter will focus on the contributing
factors to hyperglycemia in the hospitalized transplant patient,
the current knowledge about outcomes and consequences of
uncontrolled hyperglycemia after transplant, goals for glucose
control, and practical strategies and considerations for glucose
management in these populations, including the need to plan
for care transitions to home after hospital discharge.
Transplant-Related Factors that Contribute to Altered
Glucose Metabolism in the Hospitalized Transplant
Patient
Preexisting Insulin Resistance and Glucose Intolerance, In-
cluding Post-Transplant Diabetes Mellitus Frequency of im-
paired glucose tolerance and diabetes is already high in trans-
plant populations. Diabetes is the most common cause of end-
stage renal disease and need for kidney transplant in the USA
[6–8]. Diabetes is also present in 14–22 % of heart transplant
recipients [9–11] and up to a quarter of liver transplant recip-
ients [12, 13•]. Obesity is also very common in transplant
populations. Up to 60 % or more of kidney transplant recipi-
ents are overweight or obese at the time of transplant [14], and
further weight gain after transplant is common, which can
exacerbate hyperglycemia [15]. Obesity in the organ trans-
plant recipient is directly linked to insulin resistance, as shown
in kidney transplant recipients, where risk for hyperglycemia
is associated with body mass index, though not necessarily in
the immediate post-operative period after transplant [16, 17].
PTDM, as defined by older 2003 guidelines [2], is estimat-
ed to occur in 17 to 74% of kidney transplant recipients, up to
30 % of liver transplant recipients, and approximately a quar-
ter of heart transplant recipients [18–23]. Newer consensus
guidelines suggest that delaying diagnosis until persistent hy-
perglycemia is demonstrated after the recipient has been re-
duced to maintenance immunosuppression doses (Table 1)
[3•]. While hemoglobin A1c has been added as a diagnostic
criteria for diabetes by the American Diabetes Association for
diagnosis in the general population, it is associated with an
unacceptable false-negative rate for diagnosis of diabetes after
transplant due to the frequency of anemia and transfusion so
should not be as the sole screening criteria in the first year after
transplant [24]. It should be noted that even with regular
screening for diabetes, transplant patients can develop interval
PTDM that may remain asymptomatic and unrecognized until
they are hospitalized for another cause.
Immunosuppressants One of the most significant contributing
factors to hyperglycemia in the hospitalized transplant patient
is the immunosuppression required by transplantation. Corti-
costeroids have been long recognized to contribute to hyper-
glycemia by causing or exacerbating insulin resistance and
increasing hepatic gluconeogenesis [17, 25, 26]. High-dose
corticosteroids are commonly prescribed with induction, or
to treat rejection or graft-versus-host disease, as after bone
marrow transplant, in addition to being part of their long-
term immunosuppression for many. Other types of immuno-
suppressant agents also contribute to hyperglycemia including
the calcineurin inhibitors (tacrolimus more than cyclosporine)
and inhibitors of the mammalian target of rapamycin (mTOR),
such as sirolimus. Tacrolimus can reduce insulin secretion,
increase islet apoptosis, and exacerbate insulin resistance
[27–30]. Calcineurin-sparing strategies have also been shown
to be associated with less risk of PTDM and better graft sur-
vival in a meta-analysis of 56 randomized control trials [31•].
Sirolimus has been shown to be independently associated with
PTDM, in a large cohort of kidney transplant recipients in the
US Renal Data System [32]. A separate retrospective analysis
of treatment regimens also demonstrated that sirolimus predis-
poses to PTDM after kidney transplantation [33•]. Studies
in vitro show that sirolimus disrupts insulin action through
multiple effects on the insulin signal transduction pathway
and can reduce beta cell function and islet mass [28, 32,
34–36].
Nutrition Nutritional support, often required immediately af-
ter both solid organ and bone marrow transplants, can also
impact glycemic control, with or without a history of diabetes
[37]. Total parenteral nutrition (TPN) is required after all small
bowel transplants, often needed for management of graft-
versus-host disease after bone marrow transplant which af-
fects intestinal function [38, 39], and commonly used post-
transplant for other solid organ recipients when enteral nutri-
tion is contraindicated for an extended period of time. TPN
can cause hyperglycemia in all populations, and risk is greater
Table 1 Diagnosis of post-transplant diabetes mellitus
Diagnosis of post-transplant diabetes mellitus is similar to the diagnosis of
diabetes in non-transplant populations, where the testing should be
performed outside of the hospital, with no recent history of restricted
nutrition, while on maintenance immunosuppression doses. Diagnosis
can be made in the following ways [3•]:
• Fasting glucose ≥126 mg/dL (7 mmol/L) on more than one occasion
• Random glucose ≥200 mg/dL (11.1 mmol/L) with symptoms
• Oral glucose tolerance test where 2 h glucose ≥200 mg/dL
(11.1 mmol/L)
While hemoglobin A1C is allowed for diagnosis in non-transplant
patients, it is not reliable for diagnosis of PTDM in the first year after
transplant so should not be used for screening in the absence of other
testing
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for those with significant insulin resistance, which describes
many organ transplant recipients.
Infection Immunosuppression increases risk for infections of
all kinds after transplant [40], and severe infection, particular-
ly sepsis, can precipitate hyperglycemia even in those patients
with otherwise normal glucose tolerance [41]. Preexisting
chronic infections like hepatitis C or cytomegalovirus, more
common to some transplant populations, also increase risk of
hyperglycemia [42].
Improved Renal Function Insulin requirements of diabetes
patients decrease as renal disease progresses, due to reduced
insulin degradation in the kidney [43]. Thus, after successful
kidney transplant, insulin clearance by the kidney improves,
unmasking preexisting glucose intolerance to contribute to the
hyperglycemia observed in the immediate post-operative set-
ting [44].
Long-Term Consequences of Perioperative Glucose
Control
Patient and Graft Survival Glucose control improves out-
comes for many groups of non-transplant hospitalized patients
[45–50] PTDM, whether originating before or immediately
after transplant, also reduces overall graft and patient survival
after kidney transplant [51, 52]. There is also increasing rec-
ognition that perioperative glycemic control alone impacts
outcomes after transplant even in the absence of PTDM, pos-
sibly because of its associated risk of ischemia reperfusion and
delayed graft function after kidney transplant [53•, 54•]. Graft
rejection is also more frequent in kidney transplant recipients
with post-operative hyperglycemia, whether or not they have
diabetes [55–58]. In a retrospective review of liver and liver-
kidney transplant recipients, patients with higher post-
operative glucose levels (more than 200 mg/dL) had a higher
rejection rate compared to those with glucose levels less than
200 mg/dL [56].
Hyperglycemia was associated with increased risk of mor-
tality in liver transplant recipients [59]. However, to date, no
studies suggest a benefit of perioperative glycemic control
beyond that recommended for all hospitalized patients on
mortality after kidney transplant [60•].
Risk for Infection In a retrospective analysis, Van den Berg
et al. reported no correlation between post-operative blood
glucose levels and rates of post-kidney transplant infections
[61]. However, a separate retrospective analysis revealed an
increased risk of rehospitalizations for infectious complica-
tions in kidney transplant recipients who developed post-
operative hyperglycemia [62]. Since the rate of post-
operative hyperglycemia in this population (defined as two
blood glucose values >126 mg/dL) was quite low at 7.6 %,
this study may not be representative of other kidney transplant
populations or centers. Thomas et al. reported a significantly
higher rate of infections in kidney transplant recipients who
developed hyperglycemia (blood glucose >200 mg/dL) in the
first 100 h post-operatively, again suggesting that post-
operative hyperglycemia may be associated with increased
risk for infections [57].
In liver transplant recipients, Ammori and colleagues re-
ported a positive association between intraoperative glucose
>150 mg/dL and infection rate at 30 days when compared to
an intensive glucose control group (<150 mg/dL) [59]. Park
and associates also reported that in patients undergoing liver
transplantation, severe intraoperative hyperglycemia
(>200 mg/dL) was associated with increased risk of post-
operative surgical site infection when compared to those with
mean blood glucose ≤180 mg/dL [63].
Post-Transplant Diabetes Mellitus Those with higher glucose
values after transplant are also more likely to be given a diag-
nosis of PTDM, as suggested by a retrospective review of liver
transplant recipients. Elevated fasting glucose during the first
2 weeks was also associated with a greater incidence of dia-
betes after transplant [64]. Conversely, early tight glycemic
control after kidney transplant with insulin may actually re-
duce risk of later PTDM [5•].
Glucose Goals and General Approach
Glucose goals for the hospitalized transplant patient should be
the same as other hospitalized patients (ICU 140–180 mg/dL
and non-ICU premeal <140 and random <180 mg/dL) [45].
The one randomized control study of kidney transplant recip-
ients designed to assess the impact of tighter control during the
immediate hospitalization (70–110 vs <180 mg/dL) did not
improve any outcome, and the intensive group experienced
not only more hypoglycemia but also more rejection episodes,
although the latter was not statistically significant [60•]. While
it might be tempting to assume that tighter control would
improve outcomes after heart transplant, in particular, there
are no published studies. Thus, to date, more stringent glucose
control could result in worse rather than better outcomes after
transplant.
Treatment of hyperglycemia immediately after transplant is
generally initiated with and often requires an intravenous in-
sulin infusion algorithm with frequent glucose monitoring.
Many types of intravenous insulin protocols can successfully
achieve desired glucose goals, including algorithms that are
nursing-driven [65]. When the patient is ready for enteral or
parenteral nutrition, the intravenous insulin infusion should be
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transitioned to subcutaneous insulin injections appropriate to
their insulin requirements on the intravenous insulin infusion,
planned size and frequency of meals, if eating, or planned
parenteral or enteral tube feeding orders.
The insulin treatment regimen required at the time of tran-
sition is highly variable so does not readily lend itself to a
fixed insulin per kilogram dose, in part, because of the varia-
tion in kidney function, immunosuppression regimen, cortico-
steroid and other immunosuppressant doses required, severity
of obesity, and other factors that drive insulin resistance in this
group. If the patient is being given total parenteral nutrition
(TPN), 80 % of the intravenous insulin requirements over the
last 24 h are usually administered as either neutral protamine
Hagedorn (NPH) (1/3 delivered every 8 h) or glargine (either
as a once daily dose or split with half given every 12 h). The
first dose of long-acting insulin should be given at least two
and preferably 4 h before the intravenous insulin is
discontinued. If daily insulin requirements are decreasing rap-
idly, the daily requirements may be better estimated from that
used in the last 8 h and multiplying by 3 to obtain the starting
daily dose. After transitioning to subcutaneous insulin injec-
tions, glucose should be measured at the bedside at regular
intervals, either every 4 or 6 h, with a scale provided to guide
the administration of supplemental subcutaneous regular or
fast-acting analog insulin. While there is no one standard, a
starting point is often 1–2 units for every 40–50 mg/dL above
a defined glucose threshold value, that value being 150 mg/dL
in our center.
Insulin requirements can change dramatically when
transitioning off TPN, so insulin requirements should either
be reassessed off TPN before transitioning to subcutaneous
insulin or a weight-based dose of insulin should be calculated
(0.2–0.4 units/kg), of which 50 % should be used as the
starting basal insulin dose, whether the patient is being started
on enteral tube feeding or meals. Fast-acting insulin is then
used for bolus tube feedings or for meals, usually ordered as a
ratio of fast-acting insulin/grams of carbohydrates (e.g., 1–2
units/15 g as a starting dose). Again, a supplemental scale of
fast-acting insulin should be provided to address blood glu-
cose values higher than the desired range. When reliability of
food ingestion is a concern, as with frequent vomiting, the
dose should be given only after it is clear what the patient
actually ate and kept down, not based on what is ordered.
If the patient is not on TPN and is being transitioned from
clear liquids to full diet, 80 % of the intravenous insulin re-
quirements over the last 24 h are usually given as basal insulin,
most often as glargine or Levemir, with fast-acting insulin
ordered for ingested food based on an insulin/ carbohydrate
ratio, as described above.
An additional fixed dose of NPH or glargine (e.g., 10 units)
is often added to cover intermittent corticosteroid doses given
for induction or acute rejection to minimize glucose excur-
sions from this dose alone. Whenever possible, coordinating
the timing of glucocorticosteroid dose, whether planned for
oral or intravenous administration, with that of the long-acting
insulin will improve the ability to titrate the insulin dose to
cover the possible increased requirements over that interval.
When changing to subcutaneous insulin dosing, glucose test-
ing frequency and supplemental insulin orders should also be
adjusted to the timing of the subcutaneous insulin injections.
Insulin doses should be adjusted daily based on the evidence
of increasing or decreasing insulin resistance, planned chang-
es in immunosuppression dosing, significant change in kidney
function, or planned changes in nutrition strategy.
A multidisciplinary approach is essential to the manage-
ment of transplant patients. Regular conversations between
the glucose monitoring team with the nursing staff should
reinforce a need for rapid communication of any planned or
unplanned changes in immunosuppression; type, timing, fre-
quency, or discontinuation of nutrition therapy; or planned
surgery.
Diabetes education should be considered early, to include
glucose monitoring and even insulin administration training,
as intermittent use of insulin is common enough that early
training may prevent a delay in discharge. When discharge
is imminent, some can be considered for oral hypoglycemic
agents if insulin requirements are low or to simplify therapy if
there is concern that the patient or the family is having diffi-
culty in handling glucose monitoring and/or insulin therapy
after discharge. There are few available studies to assess safety
or risk of most oral hypoglycemic agents in transplant pa-
tients, and there are greater potential risks for many oral agents
as outlined in Table 2.
Transplant-Specific Considerations
Kidney Transplantation Frequent and sometimes severe shifts
in renal function are common in this population and can cause
rapid changes in insulin requirements. This can occur in the
immediate post-transplant hospitalization, as well.
Liver Transplantation Those being transplanted for hepa-
titis C, particularly if on a tacrolimus-containing regi-
men, are much more likely to develop significant hyper-
glycemia after transplant [66]. A retrospective review of
patients who underwent liver transplantation concluded
that post-operative infections were also lower in patients
on insulin infusions managed by a glucose management
service where average peri-operative glucose was
158 mg/dL, compared to those not on the glucose man-
agement service where average glucose was 189 mg/dL
[67•].
Heart Transplantation Diabetes used to be a contraindication
to heart transplant, but programs generally do not exclude
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diabetes outright, and there are no significant differences in
outcomes between diabetic and non-diabetic recipients [68•,
69•]. However, hyperglycemia is common even in non-
diabetic heart transplant recipients.
Lung Transplantation Many lung transplant recipients are
thin, so less likely to be considered at risk for diabetes, but
hyperglycemia is still common. Many patients receive lung
transplant for cystic fibrosis, and many have developed cystic
fibrosis-related diabetes prior to, or at risk for, hyperglycemia
following transplant.
Intestinal Transplant It is common that patients receiving in-
testinal transplant require parenteral nutrition longer, but there
is little data regarding the incidence of hyperglycemia or
PTDM following intestinal transplant.
Bone Marrow Transplantation The prevalence of post-
transplant hyperglycemia has been reported as high as 71 %
after bone marrow transplantation (BMT) and appears to be at
least partially dependent on whether or not patients received
parenteral nutrition [70–72]. Hyperglycemia after BMT is as-
sociated with higher rates of complications, specifically need
for red blood cell and platelet transfusion and delay in granu-
locyte and platelet engraftment times [72]. Hyperglycemia
during the neutropenic period following myeloablative allo-
geneic BMT is also associated with higher rates of organ dys-
function, acute graft-versus-host disease (GVHD), and worse
overall survival and non-relapse mortality [73].
Body mass index (BMI) and degree of hyperglycemia
within the first 10 days after transplant appear to play a sig-
nificant prognostic role for developing acute GVHD. A recent
study showed that 14.2 % of normal to overweight subjects
(normal BMI 21–24.9; overweight BMI 25–29.9) developed
severe hyperglycemia within 10 days of allogeneic BMT (glu-
cose >9.99 mmol/L), which significantly increased their risk
of acute GVHD. More obese (BMI >30 kg/m2) and no lean
(BMI <21 kg/m2) developed severe hyperglycemia, but the
risk of GVHD was unrelated to severe hyperglycemia [74•].
Because skin swelling can be severe in some patients with
GVHD, if subcutaneous insulin appears to be inadequately
absorbed, intravenous insulin infusion may be required, as
well as to achieve glucose goals in the setting of high-dose
corticosteroids or with TPN. In some protocols, TPN is given
as a 20-h infusion, which can be difficult to match with intra-
venous insulin.
Current Strategies for Prevention of PTDM
Hyperglycemia is likely to be a risk with any large surgery and
cannot be completely avoided. However, there is considerable
interest in reducing severity of hyperglycemia and strategies
that might reduce the longer-term risk of developing PTDM.
Some of these approaches are described below.
Choosing Immunosuppression Regimens Based on Diabetes
Risk PTDM can reduce graft and patient survival, but re-
jection is the number one cause of reduced graft and pa-
tient survival [75]. Since graft survival remains the most
important outcome overall, the immunosuppression regi-
men should be selected solely based on reducing graft
failure, not diabetes risk.
Table 2 Special considerations for use of oral and subcutaneous
hypoglycemic agents in transplant patients
Diabetes medication class Potential restrictions or considerations
Sulfonylureas or
repaglinide
Risk of hypoglycemia if GFR is reduced,
less with repaglinide than sulfonylureas;
potential drug-drug interactions of
sulfonylureas with cyclosporine
Metformin Should not be used in the hospital or
within 48 h of intravenous contrast
administration, known heart failure,
elevated liver function tests, or reduced
GFR
DPP-IV inhibitors Has not been studied with GFR <40 mL/
min; linagliptin least likely to require
dose adjustment for low GFR
Thiazolidinediones May be preferentially chosen for treatment
of fatty liver after liver transplant but
should generally be avoided in others
with elevated liver function tests, heart
failure, or significant peripheral edema.
May also reduce hemoglobin and bone
mass
Acarbose Avoid with low GFR; less likely to be
effective for most transplant patients
because of mild benefit
SGLT-2 inhibitors No studies to assure safety in transplant
patients; known to increase risk of
genitourinary tract infections in women
and balanitis in men so concern risk
would be greater with
immunosuppression. Because these
agents are known to reduce GFR and
can reduce blood pressure, they may
have a negative impact on kidney graft
GLP-1 agonists (e.g.,
exenatide, liraglutide)
These agents have not been studied in
transplant patients but are known to
reduce intestinal motility, which may
affect immunosuppressant
pharmacokinetics. Should not be used
with GFR <40 mL/min
There are few studies evaluating the safety or efficacy of many diabetes
therapies other than insulin. While most transplant patients will be treated
with insulin while in the hospital, some may be transitioned before dis-
charge back to other agents that they were taking prior to the hospitaliza-
tion. Co-morbidities should limit their use for specific patient groups.
GFR glomerular filtration rate, SGLT-2 sodium-glucose co-transporter-2
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Designing Immunosuppressants or Regimens with Less Risk
of PTDM Steroid-free regimens were first developed with the
hope of reducing risk of PTDM but have not been associated
with lower rates of PTDM because non-steroidal immunosup-
pressive agents also contribute to PTDM. Developing immu-
nosuppression agents or regimens with less risk of PTDM is
still a goal for many manufacturers and transplant teams.
Preventing PTDMwithHypoglycemic Agents or Insulin Multiple
trials are in progress to determine if early introduction of hy-
poglycemic therapies can protect islets and prevent later
PTDM, including dipeptidyl peptidase (DPP)-IV inhibitors,
metformin, and insulin.
DPP-IV inhibitors and metformin are used for management
of PTDM so are also attractive agents for prevention of PTDM
[76•, 77•, 78•]. Thiazolidinediones (TZD) have been shown to
be safe and efficacious in the management of diabetes after
kidney transplantation [79, 80], but the potential side effects of
TZDs have not made it an attractive prevention agent. Insulin
has been studied in the prevention of PTDM, and basal insulin
has been shown to decrease incidence of PTDM after kidney
transplant [5•]. Metformin use can be difficult in the first year
after kidney transplantation due to fluctuations in creatinine
but is being studied for prevention.
Preventing PTDM with Behavioral Interventions Intensive
lifestyle change can prevent type 2 diabetes in at risk non-
transplant populations so has been suggested as a method to
prevent PTDM. Active lifestyle modification including dieti-
tian referral, exercise program, and weight loss advice benefits
kidney transplant recipients with impaired glucose tolerance
[81] and should be incorporated into any preventive measure.
Summary and Conclusions
Hyperglycemia is common immediately after solid organ
transplant and predicts greater risk for PTDM. Management
of hyperglycemia in the immediate post-operative period is
challenging because transplant recipients often have reduced
or changing kidney function, experience unpredictable chang-
es in nutrition due to nausea and vomiting and frequent need
for parenteral and enteral nutrition, require treatment with
types and doses of immunosuppression agents that can dra-
matically impact glucose intolerance, and have other events
like surgery and infections or pain that can aggravate
preexisting insulin resistance. Glucose goals in the hospital
are the same for transplant recipients as any other hospitalized
patient, but transplant recipients are at greater risk for hypo-
glycemia because of the frequent and potentially rapid chang-
es in factors that impact glucose (renal function, nutrition,
“stress,” and medications). It is critical that all consulting
teams work together as well as with the nursing team to an-
ticipate and rapidly respond to any changes in status that
might warrant a change in intravenous insulin protocol or
other pharmacologic therapy. Planning for discharge is even
more important than other hospitalized patients, as ongoing
changes in insulin resistance can continue to occur very rap-
idly. The patient needs to understand when and how to contact
the team if significant changes in glucose, high or low, occur
after discharge.
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